ZOLL data breach impacted 277,319 patients

More than a quarter-million people were recently affected by a ZOLL Medical data breach that exposed patient names, addresses, dates of birth, limited medical information and some Social Security numbers, the company announced.

ZOLL reported the breach to HHS March 18 after learning of the incident Jan. 24, according to a press release. The company said some data from ZOLL emails—which are archived by a third-party service provider—were exposed during a server migration between Nov. 8, 2018, and Dec. 28, 2018.

“At this point, ZOLL is not aware of any fraud or identity theft to any individual as a result of this exposure,” the release read. “The vendor has since confirmed that all information has now been secured.”

Information that could have been exposed in the breach included patient names, addresses, dates of birth and a small percentage of Social Security numbers, ZOLL said, as well as some medical information.

The company is offering free credit and yearlong identity monitoring services to patients affected by the breach and said it’s taking steps to review its process for managing third-party vendors. Law enforcement and federal agencies have been notified of the incident for further investigation.

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.